Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2023 13:00 ET | Source: DelveInsight Business Research LLP

PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the Therapeutics Landscape

New York, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- PARP Inhibitors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 20+ Leading Players Wheeling the...
July 05, 2023 07:15 ET | Source: Transparency Market Research

DNA Repair Drugs Market to Grow at 6.5% CAGR, Touching US$ 10.4 Bn by 2031: TMR Study

Wilmington, Delaware, United States, July 05, 2023 (GLOBE NEWSWIRE) -- The global DNA repair drugs market was valued at US$ 5.9 Bn in 2022 and is projected to reach US$ 10.4 Bn by 2031 with CAGR of...
January 11, 2023 11:30 ET | Source: Future Market Insights Global and Consulting Pvt. Ltd.

PCSK9 Inhibitors Market Sales to expand at a 15.8% CAGR from 2023 to 2033, Repatha-based Inhibitors to be Most Widely Used: Future Market Insights, Inc.

NEWARK, Del, Jan. 11, 2023 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global PCSK9 inhibitors market to augment at a 15.8% CAGR from 2022 to 2032. By the end of the said...
September 08, 2021 09:00 ET | Source: Roots Analysis

The DNA damage response (DDR) targeting therapeutics market is projected to be worth USD 1.07 billion in 2030, growing at an annualized rate of 52.6% during the period 2024-2030, claims Roots Analysis

London, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “DNA Damage Response Targeting Therapeutics (beyond PARP inhibitors) Market, 2021-2030” report to its list of...
April 01, 2019 07:00 ET | Source: Cyclacel

Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
September 10, 2018 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...